Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited Free Cash Flow for the year ending June 30, 2024: USD -4.01 M

Regencell Bioscience Holdings Limited Free Cash Flow is USD -4.01 M for the year ending June 30, 2024, a 19.70% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Regencell Bioscience Holdings Limited Free Cash Flow for the year ending June 30, 2023 was USD -4.99 M, a 17.49% change year over year.
Regencell Bioscience Holdings Limited Free Cash Flow for the year ending June 30, 2022 was USD -6.05 M.
Regencell Bioscience Holdings Limited Free Cash Flow for the year ending June 30, 2020 was USD -844.41 K.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years